GlassScriptPhysician profile
Gurvinder K Deogun
NPI 1043395171
$14,264.54
in general payments reported to CMS, 2019-2025
38 companies · $2,565 in 2025
The $2,565 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,424 · 2020: $696 · 2021: $1,740 · 2022: $2,013 · 2023: $2,364 · 2024: $2,463 · 2025: $2,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,243 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,243.28 |
| Education | $149.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,367.63 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,624.04 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,018.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Csl Behring | $943.12 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Amgen INC. | $880.08 | 2021-2025 | Tezspire |
| Pfizer INC. | $798.94 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $577.36 | 2019-2025 | |
| Abbvie INC. | $533.91 | 2021-2024 | Rinvoq |
| Genentech USA, INC. | $414.63 | 2019-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $389.20 | 2020-2025 | Eohilia, Takhzyro, Hyqvia |
| Genzyme Corporation | $373.04 | 2019-2024 | |
| Biocryst US Sales Co., LLC | $353.71 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $311.55 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $245.55 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Optinose US, INC. | $200.75 | 2019-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurvinder Deogun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.